Glenmede Trust Co. NA Has $19.42 Million Stake in Globus Medical, Inc. $GMED

Glenmede Trust Co. NA raised its holdings in Globus Medical, Inc. (NYSE:GMED) by 22.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 225,446 shares of the medical device company’s stock after purchasing an additional 41,801 shares during the period. Glenmede Trust Co. NA’s holdings in Globus Medical were worth $19,424,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Sanctuary Advisors LLC increased its holdings in shares of Globus Medical by 2.3% during the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after purchasing an additional 151 shares during the period. SBI Securities Co. Ltd. boosted its stake in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the period. Parallel Advisors LLC boosted its stake in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Finally, Allworth Financial LP grew its position in Globus Medical by 1.6% during the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock worth $1,095,000 after buying an additional 199 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company cut their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. BMO Capital Markets started coverage on Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price on the stock. Piper Sandler decreased their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research report on Monday, June 15th. Finally, Needham & Company LLC raised their price target on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 18.38% of the company’s stock.

Globus Medical Trading Down 1.6%

GMED stock opened at $78.99 on Friday. The stock has a market capitalization of $10.72 billion, a P/E ratio of 18.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.95. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The firm has a 50-day moving average price of $79.53 and a 200-day moving average price of $85.61.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, equities analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.